Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Invested Capital (2024 - 2025)

Historic Invested Capital for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $58.5 million.

  • Prelude Therapeutics' Invested Capital fell 6258.16% to $58.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.5 million, marking a year-over-year decrease of 6258.16%. This contributed to the annual value of $131.5 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Prelude Therapeutics reported Invested Capital of $58.5 million as of Q3 2025, which was down 6258.16% from $75.8 million recorded in Q2 2025.
  • Prelude Therapeutics' Invested Capital's 5-year high stood at $210.7 million during Q1 2024, with a 5-year trough of $58.5 million in Q3 2025.